Attention Deficit Hyperactivity Disorder Therapeutics Market, Global Outlook and Forecast 2022-2028

February 2022 | 60 pages | ID: A5210B9EA314EN
Market Monitor Global

Abstracts

Attention deficit hyperactivity disorder (ADHD) is a mental health disorder that can cause above-normal levels of hyperactive and impulsive behaviors.

This report contains market size and forecasts of Attention Deficit Hyperactivity Disorder Therapeutics in Global, including the following market information:

Global Attention Deficit Hyperactivity Disorder Therapeutics Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Attention Deficit Hyperactivity Disorder Therapeutics market was valued at 18360 million in 2021 and is projected to reach US$ 24470 million by 2028, at a CAGR of 4.2% during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Stimulant Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Attention Deficit Hyperactivity Disorder Therapeutics include Takeda, Johnson & Johnson, Novartis, Eli Lilly, Tris Pharma, Neos Therapeutics, Mallinckrodt, Amneal Pharmaceuticals and Noven Pharmaceuticals and etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Attention Deficit Hyperactivity Disorder Therapeutics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Attention Deficit Hyperactivity Disorder Therapeutics Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Attention Deficit Hyperactivity Disorder Therapeutics Market Segment Percentages, by Type, 2021 (%)

• Stimulant
• Non-stimulant

Global Attention Deficit Hyperactivity Disorder Therapeutics Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Attention Deficit Hyperactivity Disorder Therapeutics Market Segment Percentages, by Application, 2021 (%)

• Hospital Pharmacy
• Retail Pharmacy

Global Attention Deficit Hyperactivity Disorder Therapeutics Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Attention Deficit Hyperactivity Disorder Therapeutics Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Attention Deficit Hyperactivity Disorder Therapeutics revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Attention Deficit Hyperactivity Disorder Therapeutics revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Takeda
• Johnson & Johnson
• Novartis
• Eli Lilly
• Tris Pharma
• Neos Therapeutics
• Mallinckrodt
• Amneal Pharmaceuticals
• Noven Pharmaceuticals
• Purdue Parma

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Attention Deficit Hyperactivity Disorder Therapeutics Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Attention Deficit Hyperactivity Disorder Therapeutics Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER THERAPEUTICS OVERALL MARKET SIZE

2.1 Global Attention Deficit Hyperactivity Disorder Therapeutics Market Size: 2021 VS 2028
2.2 Global Attention Deficit Hyperactivity Disorder Therapeutics Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Attention Deficit Hyperactivity Disorder Therapeutics Players in Global Market
3.2 Top Global Attention Deficit Hyperactivity Disorder Therapeutics Companies Ranked by Revenue
3.3 Global Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Companies
3.4 Top 3 and Top 5 Attention Deficit Hyperactivity Disorder Therapeutics Companies in Global Market, by Revenue in 2021
3.5 Global Companies Attention Deficit Hyperactivity Disorder Therapeutics Product Type
3.6 Tier 1, Tier 2 and Tier 3 Attention Deficit Hyperactivity Disorder Therapeutics Players in Global Market
  3.6.1 List of Global Tier 1 Attention Deficit Hyperactivity Disorder Therapeutics Companies
  3.6.2 List of Global Tier 2 and Tier 3 Attention Deficit Hyperactivity Disorder Therapeutics Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global Attention Deficit Hyperactivity Disorder Therapeutics Market Size Markets, 2021 & 2028
  4.1.2 Stimulant
  4.1.3 Non-stimulant
4.2 By Type - Global Attention Deficit Hyperactivity Disorder Therapeutics Revenue & Forecasts
  4.2.1 By Type - Global Attention Deficit Hyperactivity Disorder Therapeutics Revenue, 2017-2022
  4.2.2 By Type - Global Attention Deficit Hyperactivity Disorder Therapeutics Revenue, 2023-2028
  4.2.3 By Type - Global Attention Deficit Hyperactivity Disorder Therapeutics Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Attention Deficit Hyperactivity Disorder Therapeutics Market Size, 2021 & 2028
  5.1.2 Hospital Pharmacy
  5.1.3 Retail Pharmacy
5.2 By Application - Global Attention Deficit Hyperactivity Disorder Therapeutics Revenue & Forecasts
  5.2.1 By Application - Global Attention Deficit Hyperactivity Disorder Therapeutics Revenue, 2017-2022
  5.2.2 By Application - Global Attention Deficit Hyperactivity Disorder Therapeutics Revenue, 2023-2028
  5.2.3 By Application - Global Attention Deficit Hyperactivity Disorder Therapeutics Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Attention Deficit Hyperactivity Disorder Therapeutics Market Size, 2021 & 2028
6.2 By Region - Global Attention Deficit Hyperactivity Disorder Therapeutics Revenue & Forecasts
  6.2.1 By Region - Global Attention Deficit Hyperactivity Disorder Therapeutics Revenue, 2017-2022
  6.2.2 By Region - Global Attention Deficit Hyperactivity Disorder Therapeutics Revenue, 2023-2028
  6.2.3 By Region - Global Attention Deficit Hyperactivity Disorder Therapeutics Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America Attention Deficit Hyperactivity Disorder Therapeutics Revenue, 2017-2028
  6.3.2 US Attention Deficit Hyperactivity Disorder Therapeutics Market Size, 2017-2028
  6.3.3 Canada Attention Deficit Hyperactivity Disorder Therapeutics Market Size, 2017-2028
  6.3.4 Mexico Attention Deficit Hyperactivity Disorder Therapeutics Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe Attention Deficit Hyperactivity Disorder Therapeutics Revenue, 2017-2028
  6.4.2 Germany Attention Deficit Hyperactivity Disorder Therapeutics Market Size, 2017-2028
  6.4.3 France Attention Deficit Hyperactivity Disorder Therapeutics Market Size, 2017-2028
  6.4.4 U.K. Attention Deficit Hyperactivity Disorder Therapeutics Market Size, 2017-2028
  6.4.5 Italy Attention Deficit Hyperactivity Disorder Therapeutics Market Size, 2017-2028
  6.4.6 Russia Attention Deficit Hyperactivity Disorder Therapeutics Market Size, 2017-2028
  6.4.7 Nordic Countries Attention Deficit Hyperactivity Disorder Therapeutics Market Size, 2017-2028
  6.4.8 Benelux Attention Deficit Hyperactivity Disorder Therapeutics Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia Attention Deficit Hyperactivity Disorder Therapeutics Revenue, 2017-2028
  6.5.2 China Attention Deficit Hyperactivity Disorder Therapeutics Market Size, 2017-2028
  6.5.3 Japan Attention Deficit Hyperactivity Disorder Therapeutics Market Size, 2017-2028
  6.5.4 South Korea Attention Deficit Hyperactivity Disorder Therapeutics Market Size, 2017-2028
  6.5.5 Southeast Asia Attention Deficit Hyperactivity Disorder Therapeutics Market Size, 2017-2028
  6.5.6 India Attention Deficit Hyperactivity Disorder Therapeutics Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America Attention Deficit Hyperactivity Disorder Therapeutics Revenue, 2017-2028
  6.6.2 Brazil Attention Deficit Hyperactivity Disorder Therapeutics Market Size, 2017-2028
  6.6.3 Argentina Attention Deficit Hyperactivity Disorder Therapeutics Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Attention Deficit Hyperactivity Disorder Therapeutics Revenue, 2017-2028
  6.7.2 Turkey Attention Deficit Hyperactivity Disorder Therapeutics Market Size, 2017-2028
  6.7.3 Israel Attention Deficit Hyperactivity Disorder Therapeutics Market Size, 2017-2028
  6.7.4 Saudi Arabia Attention Deficit Hyperactivity Disorder Therapeutics Market Size, 2017-2028
  6.7.5 UAE Attention Deficit Hyperactivity Disorder Therapeutics Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Takeda
  7.1.1 Takeda Corporate Summary
  7.1.2 Takeda Business Overview
  7.1.3 Takeda Attention Deficit Hyperactivity Disorder Therapeutics Major Product Offerings
  7.1.4 Takeda Attention Deficit Hyperactivity Disorder Therapeutics Revenue in Global Market (2017-2022)
  7.1.5 Takeda Key News
7.2 Johnson & Johnson
  7.2.1 Johnson & Johnson Corporate Summary
  7.2.2 Johnson & Johnson Business Overview
  7.2.3 Johnson & Johnson Attention Deficit Hyperactivity Disorder Therapeutics Major Product Offerings
  7.2.4 Johnson & Johnson Attention Deficit Hyperactivity Disorder Therapeutics Revenue in Global Market (2017-2022)
  7.2.5 Johnson & Johnson Key News
7.3 Novartis
  7.3.1 Novartis Corporate Summary
  7.3.2 Novartis Business Overview
  7.3.3 Novartis Attention Deficit Hyperactivity Disorder Therapeutics Major Product Offerings
  7.3.4 Novartis Attention Deficit Hyperactivity Disorder Therapeutics Revenue in Global Market (2017-2022)
  7.3.5 Novartis Key News
7.4 Eli Lilly
  7.4.1 Eli Lilly Corporate Summary
  7.4.2 Eli Lilly Business Overview
  7.4.3 Eli Lilly Attention Deficit Hyperactivity Disorder Therapeutics Major Product Offerings
  7.4.4 Eli Lilly Attention Deficit Hyperactivity Disorder Therapeutics Revenue in Global Market (2017-2022)
  7.4.5 Eli Lilly Key News
7.5 Tris Pharma
  7.5.1 Tris Pharma Corporate Summary
  7.5.2 Tris Pharma Business Overview
  7.5.3 Tris Pharma Attention Deficit Hyperactivity Disorder Therapeutics Major Product Offerings
  7.5.4 Tris Pharma Attention Deficit Hyperactivity Disorder Therapeutics Revenue in Global Market (2017-2022)
  7.5.5 Tris Pharma Key News
7.6 Neos Therapeutics
  7.6.1 Neos Therapeutics Corporate Summary
  7.6.2 Neos Therapeutics Business Overview
  7.6.3 Neos Therapeutics Attention Deficit Hyperactivity Disorder Therapeutics Major Product Offerings
  7.6.4 Neos Therapeutics Attention Deficit Hyperactivity Disorder Therapeutics Revenue in Global Market (2017-2022)
  7.6.5 Neos Therapeutics Key News
7.7 Mallinckrodt
  7.7.1 Mallinckrodt Corporate Summary
  7.7.2 Mallinckrodt Business Overview
  7.7.3 Mallinckrodt Attention Deficit Hyperactivity Disorder Therapeutics Major Product Offerings
  7.7.4 Mallinckrodt Attention Deficit Hyperactivity Disorder Therapeutics Revenue in Global Market (2017-2022)
  7.7.5 Mallinckrodt Key News
7.8 Amneal Pharmaceuticals
  7.8.1 Amneal Pharmaceuticals Corporate Summary
  7.8.2 Amneal Pharmaceuticals Business Overview
  7.8.3 Amneal Pharmaceuticals Attention Deficit Hyperactivity Disorder Therapeutics Major Product Offerings
  7.8.4 Amneal Pharmaceuticals Attention Deficit Hyperactivity Disorder Therapeutics Revenue in Global Market (2017-2022)
  7.8.5 Amneal Pharmaceuticals Key News
7.9 Noven Pharmaceuticals
  7.9.1 Noven Pharmaceuticals Corporate Summary
  7.9.2 Noven Pharmaceuticals Business Overview
  7.9.3 Noven Pharmaceuticals Attention Deficit Hyperactivity Disorder Therapeutics Major Product Offerings
  7.9.4 Noven Pharmaceuticals Attention Deficit Hyperactivity Disorder Therapeutics Revenue in Global Market (2017-2022)
  7.9.5 Noven Pharmaceuticals Key News
7.10 Purdue Parma
  7.10.1 Purdue Parma Corporate Summary
  7.10.2 Purdue Parma Business Overview
  7.10.3 Purdue Parma Attention Deficit Hyperactivity Disorder Therapeutics Major Product Offerings
  7.10.4 Purdue Parma Attention Deficit Hyperactivity Disorder Therapeutics Revenue in Global Market (2017-2022)
  7.10.5 Purdue Parma Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Attention Deficit Hyperactivity Disorder Therapeutics Market Opportunities & Trends in Global Market
Table 2. Attention Deficit Hyperactivity Disorder Therapeutics Market Drivers in Global Market
Table 3. Attention Deficit Hyperactivity Disorder Therapeutics Market Restraints in Global Market
Table 4. Key Players of Attention Deficit Hyperactivity Disorder Therapeutics in Global Market
Table 5. Top Attention Deficit Hyperactivity Disorder Therapeutics Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Attention Deficit Hyperactivity Disorder Therapeutics Revenue Share by Companies, 2017-2022
Table 8. Global Companies Attention Deficit Hyperactivity Disorder Therapeutics Product Type
Table 9. List of Global Tier 1 Attention Deficit Hyperactivity Disorder Therapeutics Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Attention Deficit Hyperactivity Disorder Therapeutics Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Attention Deficit Hyperactivity Disorder Therapeutics Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Attention Deficit Hyperactivity Disorder Therapeutics Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Attention Deficit Hyperactivity Disorder Therapeutics Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Attention Deficit Hyperactivity Disorder Therapeutics Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Attention Deficit Hyperactivity Disorder Therapeutics Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Attention Deficit Hyperactivity Disorder Therapeutics Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Attention Deficit Hyperactivity Disorder Therapeutics Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Attention Deficit Hyperactivity Disorder Therapeutics Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Attention Deficit Hyperactivity Disorder Therapeutics Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Attention Deficit Hyperactivity Disorder Therapeutics Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Attention Deficit Hyperactivity Disorder Therapeutics Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Attention Deficit Hyperactivity Disorder Therapeutics Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Attention Deficit Hyperactivity Disorder Therapeutics Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Attention Deficit Hyperactivity Disorder Therapeutics Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Attention Deficit Hyperactivity Disorder Therapeutics Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Attention Deficit Hyperactivity Disorder Therapeutics Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Attention Deficit Hyperactivity Disorder Therapeutics Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Attention Deficit Hyperactivity Disorder Therapeutics Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Attention Deficit Hyperactivity Disorder Therapeutics Revenue, (US$, Mn), 2023-2028
Table 30. Takeda Corporate Summary
Table 31. Takeda Attention Deficit Hyperactivity Disorder Therapeutics Product Offerings
Table 32. Takeda Attention Deficit Hyperactivity Disorder Therapeutics Revenue (US$, Mn), (2017-2022)
Table 33. Johnson & Johnson Corporate Summary
Table 34. Johnson & Johnson Attention Deficit Hyperactivity Disorder Therapeutics Product Offerings
Table 35. Johnson & Johnson Attention Deficit Hyperactivity Disorder Therapeutics Revenue (US$, Mn), (2017-2022)
Table 36. Novartis Corporate Summary
Table 37. Novartis Attention Deficit Hyperactivity Disorder Therapeutics Product Offerings
Table 38. Novartis Attention Deficit Hyperactivity Disorder Therapeutics Revenue (US$, Mn), (2017-2022)
Table 39. Eli Lilly Corporate Summary
Table 40. Eli Lilly Attention Deficit Hyperactivity Disorder Therapeutics Product Offerings
Table 41. Eli Lilly Attention Deficit Hyperactivity Disorder Therapeutics Revenue (US$, Mn), (2017-2022)
Table 42. Tris Pharma Corporate Summary
Table 43. Tris Pharma Attention Deficit Hyperactivity Disorder Therapeutics Product Offerings
Table 44. Tris Pharma Attention Deficit Hyperactivity Disorder Therapeutics Revenue (US$, Mn), (2017-2022)
Table 45. Neos Therapeutics Corporate Summary
Table 46. Neos Therapeutics Attention Deficit Hyperactivity Disorder Therapeutics Product Offerings
Table 47. Neos Therapeutics Attention Deficit Hyperactivity Disorder Therapeutics Revenue (US$, Mn), (2017-2022)
Table 48. Mallinckrodt Corporate Summary
Table 49. Mallinckrodt Attention Deficit Hyperactivity Disorder Therapeutics Product Offerings
Table 50. Mallinckrodt Attention Deficit Hyperactivity Disorder Therapeutics Revenue (US$, Mn), (2017-2022)
Table 51. Amneal Pharmaceuticals Corporate Summary
Table 52. Amneal Pharmaceuticals Attention Deficit Hyperactivity Disorder Therapeutics Product Offerings
Table 53. Amneal Pharmaceuticals Attention Deficit Hyperactivity Disorder Therapeutics Revenue (US$, Mn), (2017-2022)
Table 54. Noven Pharmaceuticals Corporate Summary
Table 55. Noven Pharmaceuticals Attention Deficit Hyperactivity Disorder Therapeutics Product Offerings
Table 56. Noven Pharmaceuticals Attention Deficit Hyperactivity Disorder Therapeutics Revenue (US$, Mn), (2017-2022)
Table 57. Purdue Parma Corporate Summary
Table 58. Purdue Parma Attention Deficit Hyperactivity Disorder Therapeutics Product Offerings
Table 59. Purdue Parma Attention Deficit Hyperactivity Disorder Therapeutics Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Attention Deficit Hyperactivity Disorder Therapeutics Segment by Type in 2021
Figure 2. Attention Deficit Hyperactivity Disorder Therapeutics Segment by Application in 2021
Figure 3. Global Attention Deficit Hyperactivity Disorder Therapeutics Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Attention Deficit Hyperactivity Disorder Therapeutics Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Attention Deficit Hyperactivity Disorder Therapeutics Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Attention Deficit Hyperactivity Disorder Therapeutics Revenue in 2021
Figure 8. By Type - Global Attention Deficit Hyperactivity Disorder Therapeutics Revenue Market Share, 2017-2028
Figure 9. By Application - Global Attention Deficit Hyperactivity Disorder Therapeutics Revenue Market Share, 2017-2028
Figure 10. By Region - Global Attention Deficit Hyperactivity Disorder Therapeutics Revenue Market Share, 2017-2028
Figure 11. By Country - North America Attention Deficit Hyperactivity Disorder Therapeutics Revenue Market Share, 2017-2028
Figure 12. US Attention Deficit Hyperactivity Disorder Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Attention Deficit Hyperactivity Disorder Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Attention Deficit Hyperactivity Disorder Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Attention Deficit Hyperactivity Disorder Therapeutics Revenue Market Share, 2017-2028
Figure 16. Germany Attention Deficit Hyperactivity Disorder Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 17. France Attention Deficit Hyperactivity Disorder Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Attention Deficit Hyperactivity Disorder Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Attention Deficit Hyperactivity Disorder Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Attention Deficit Hyperactivity Disorder Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Attention Deficit Hyperactivity Disorder Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Attention Deficit Hyperactivity Disorder Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Attention Deficit Hyperactivity Disorder Therapeutics Revenue Market Share, 2017-2028
Figure 24. China Attention Deficit Hyperactivity Disorder Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Attention Deficit Hyperactivity Disorder Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Attention Deficit Hyperactivity Disorder Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Attention Deficit Hyperactivity Disorder Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 28. India Attention Deficit Hyperactivity Disorder Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Attention Deficit Hyperactivity Disorder Therapeutics Revenue Market Share, 2017-2028
Figure 30. Brazil Attention Deficit Hyperactivity Disorder Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Attention Deficit Hyperactivity Disorder Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Attention Deficit Hyperactivity Disorder Therapeutics Revenue Market Share, 2017-2028
Figure 33. Turkey Attention Deficit Hyperactivity Disorder Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Attention Deficit Hyperactivity Disorder Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Attention Deficit Hyperactivity Disorder Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Attention Deficit Hyperactivity Disorder Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 37. Takeda Attention Deficit Hyperactivity Disorder Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Johnson & Johnson Attention Deficit Hyperactivity Disorder Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Novartis Attention Deficit Hyperactivity Disorder Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Eli Lilly Attention Deficit Hyperactivity Disorder Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Tris Pharma Attention Deficit Hyperactivity Disorder Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Neos Therapeutics Attention Deficit Hyperactivity Disorder Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Mallinckrodt Attention Deficit Hyperactivity Disorder Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Amneal Pharmaceuticals Attention Deficit Hyperactivity Disorder Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Noven Pharmaceuticals Attention Deficit Hyperactivity Disorder Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. Purdue Parma Attention Deficit Hyperactivity Disorder Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)